The Hill: Regeneron Pharmaceuticals said Friday it has paused a clinical study of its antibody drug to treat some of the sickest COVID-19 patients because of a potential safety concern.
The recommendation from an independent monitoring board marks the second time a clinical trial of an experimental coronavirus antibody drug has been paused because of safety issues.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now